Omalizumab as a treatment option for antihistamine-refractory aquagenic urticaria

Overview

cited authors

Kaur, Sehajpreet; Jabbal, Iktej Singh; Bhasin, Arveen Kaur

Publication Date

July 1, 2022

webpage

Web of Science

published in

BMJ CASE REPORTS Journal

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.